210 related articles for article (PubMed ID: 15515406)
1. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
Haus U; Späth M; Färber L
Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
[TBL] [Abstract][Full Text] [Related]
2. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
3. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
5. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
6. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Balfour JA; Goa KL
Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
[TBL] [Abstract][Full Text] [Related]
7. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
8. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
Mahesh R; Perumal RV; Pandi PV
Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of 5-HT3 receptor antagonists: clinical overview and nursing implications.
Bremerkamp M
Clin J Oncol Nurs; 2000; 4(5):201-7. PubMed ID: 11111451
[TBL] [Abstract][Full Text] [Related]
10. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
11. Optimising antiemetic therapy: what are the problems and how can they be overcome?
Aapro M
Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
[TBL] [Abstract][Full Text] [Related]
12. Anti-emetic therapy in cancer chemotherapy: current status.
Herrstedt J; Dombernowsky P
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
[TBL] [Abstract][Full Text] [Related]
13. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting.
Janicki PK
Med Sci Monit; 2005 Oct; 11(10):RA322-8. PubMed ID: 16192915
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the safety of 5-HT3 antagonists with dexamethasone or droperidol for prevention of PONV.
Leslie JB; Gan TJ
Ann Pharmacother; 2006 May; 40(5):856-72. PubMed ID: 16670360
[TBL] [Abstract][Full Text] [Related]
16. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
Constenla M
Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
[TBL] [Abstract][Full Text] [Related]
17. The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.
Faerber L; Drechsler S; Ladenburger S; Gschaidmeier H; Fischer W
Eur J Pharmacol; 2007 Mar; 560(1):1-8. PubMed ID: 17316606
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis of postoperative nausea and vomiting: controversies in the use of serotonin 5-hydroxytryptamine subtype 3 receptor antagonists.
Kovac AL
J Clin Anesth; 2006 Jun; 18(4):304-18. PubMed ID: 16797435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
